1
Companies Filed At
4
Open-Market Buys (2yr)
$144K
Buy Value (2yr, open-market)
Jan 23, 2026
Most Recent Trade
26
Credibility
Score
Score
75%
Hit Rate
+46.6%
Avg 90d Return
+51.2%
Median 90d Return
4
Evaluated Trades
+90.2%
Best Trade
-6.3%
Worst Trade
Hit rate and returns are based on 4 open-market buys with evaluable
90-day outcomes. Score reflects historical conviction, not a guarantee of future performance.
Limited signal — either below-average timing or insufficient trade history.
Political Donations · Elections Canada
$2K in individual political contributions across 3 donations (2013–2023).
| Date | Party | Amount |
|---|---|---|
| 2023-12-29 | Conservative Party of Canada | $400 |
| 2015-12-29 | Conservative Party of Canada | $750 |
| 2013-12-30 | Conservative Party of Canada | $751 |
Source: Elections Canada public contribution records (individual donations only; corporate political donations have been banned federally since 2007). Matched to this insider by name — shown for transparency, not a claim of wrongdoing and not a Signal Score input.
| Date | Company | Dir. | Value |
|---|---|---|---|
| Jan 23, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $56K |
| Jan 23, 2026 |
$EPRX
Eupraxia Pharmaceuticals
|
Sell | $56K |
| Dec 15, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $207K |
| Dec 15, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $207K |
| Nov 24, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $62K |
| Nov 24, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $42K |
| Nov 24, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $13K |
| Nov 24, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $27K |
| Mar 25, 2025 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $360K |
| May 13, 2024 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $277K |
| Aug 18, 2023 |
$EPRX
Eupraxia Pharmaceuticals
|
Sell | $35K |
| Mar 30, 2023 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $4K |
| Mar 29, 2023 |
$EPRX
Eupraxia Pharmaceuticals
|
Buy | $37K |
Muted rows are plan purchases, compensation grants, or DRIP — not open-market.
Signal scores reflect the company's current score, not the score at time of trade.